ReviewMethods in molecular biology (Clifton, N.J.)2025
Targeting Key Stages of the Viral Entry and Life Cycle: A Comprehensive Overview of the Mechanisms of Antiviral Actions.
Review in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Design and synthesis of benzothiazole-sulfonate conjugates targeting influenza A (H1N1) and human coronavirus HCoV-229E:RSC advances · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiviral drugs represent diverse compounds that interfere with processes related to the survival and transmission of viruses. The pharmacology of antiviral agents covers a wide range of mechanisms targeting various stages of the viral life cycle. This write-up aims to explain the different mechanisms of antiviral drugs to combat viral infections effectively. For this, key strategies include inhibiting viral entry, replication, assembly, and release. For example, entry inhibitors, such as fusion inhibitors and receptor antagonists, prevent viruses from entering host cells. Integrase inhibitors and nucleoside/nonnucleoside reverse transcriptase inhibitors block viral replication. On the other hand, protease inhibitors obstruct the posttranslational processing of viral proteins, thus impeding viral assembly. Moreover, newer classes of drugs targeting the virus's release and maturation stages are emerging as potent therapeutic options, offering hope for more effective treatments in the future.
Indexed as
Identifiers
40455163What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.